This prospective, short-term clinical trial used the latest consensus on CYP2D6 genotype-to-phenotype translation in elderly Chinese Han patients with cardiovascular diseases and found that IMs have lower tolerance for metoprolol and higher incidence of metoprolol-related adverse events than NMs. The gene discussed is CYP2D6; the disease is cardiovascular disorder.